BridgeBio Pharma announced that its Phase 3 PROPEL 3 trial for oral infigratinib met its primary endpoint, showing a statistically significant increase in annualized height velocity of +2.10 cm per year (least‑squares mean +1.74 cm per year) versus placebo. The study also achieved the first statistically significant improvement in body proportionality in children younger than 8 years, with a least‑squares mean difference of –0.05 versus placebo, and met the key secondary endpoint of change from baseline in height Z‑score, increasing by +0.41 SD. Safety data were favorable, with no discontinuations or serious adverse events related to the drug; only three cases (4 %) of mild, transient hyperphosphatemia were reported, none requiring dose adjustment.
The results position infigratinib as a first‑in‑class oral therapy for achondroplasia, offering a non‑injectable alternative to the current injectable treatment Voxzogo. The significant improvement in body proportionality is a first for any achondroplasia therapy and could support premium pricing. The Breakthrough Therapy designation from the FDA underscores the potential for accelerated review.
Daniela Rogoff, M.D., Chief Medical Officer, Skeletal Dysplasias of BridgeBio, said: "There remains a significant unmet need for therapeutic options that are effective, practical, and less invasive for children living with achondroplasia. The PROPEL 3 data support the potential of an oral medicine directly targeting FGFR3 overactivity to address important clinical needs, while fitting into daily life for families who are seeking a non‑injectable option. These results represent meaningful progress for those who have been waiting for a better approach, and we look forward to advancing this program towards global submissions." Ravi Savarirayan, M.D., Ph.D., global lead investigator for PROPEL 3, added: "Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone, with consequences on physical functioning and independence that can impact widely over a person's lifetime. Infigratinib is the first oral therapy designed to target FGFR3 and directly address the underlying cause of achondroplasia."
BridgeBio plans to submit a New Drug Application and Marketing Authorization Application in the second half of 2026, leveraging the drug’s Breakthrough Therapy designation. The company also intends to accelerate development of infigratinib in hypochondroplasia and in infants and toddlers with achondroplasia, broadening its skeletal dysplasia portfolio.
Analysts responded positively to the data. Mizuho described the results as "incredibly clean on both efficacy and safety," noting that the body proportionality improvement could allow for premium pricing. Truist Securities said infigratinib "meaningfully exceeded even the most optimistic expectations," while Cowen’s Tyler Van Buren highlighted the first statistically significant gain in body proportionality and the once‑per‑day oral dosing as resetting the competitive bar. Leerink Partners’ Mani Foroohar estimated that the outcome could add approximately $2 billion in value to BridgeBio’s shares.
The achievement places BridgeBio in a strong position to capture a share of the estimated $1.5 billion achondroplasia market in the United States and Europe, where about 10,000 children are eligible for treatment. The oral formulation offers a clear advantage over the injectable Voxzogo and the pending TransCon CNP, potentially enabling higher uptake and pricing power. The positive Phase 3 data also support BridgeBio’s broader strategy of expanding its rare‑disease pipeline and may accelerate investor confidence in the company’s ability to bring new therapies to market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.